ArticleACS omega2025
Effects of Apilarnil on Type 2 Diabetes-Induced IRS-1/PI3K/Akt Mediated Insulin Resistance in Male Rats.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Influence and treatment of insulin receptor substrate/PI3K/Akt‑mediated insulin resistance in diabetes mellitus (Review).Molecular medicine reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is one of the most important chronic and metabolic health problems seen as an epidemic of the 21st century. The incidence of diabetes is gradually increasing, and different methods are used to treat it. Apitherapy products such as honey, propolis, royal jelly, and bee venom can be used as an alternative to treat diabetes and reduce symptoms. One of these apitherapy products is Apilarnil, which has not yet become popular. The hypolipidemic, hepatoprotective, androgenic, anabolic, and immune system enhancing properties of Apilarnil indicate that it may be effective in the treatment of type 2 diabetes or in reducing the symptoms. The study aimed to determine the therapeutic effect of Apilarnil on insulin resistance and the possible underlying mechanism. In the study, 40 8 week-old male Wistar albino rats were used. The rats were divided into 5 groups as Control, Diabetes, Diabetes + Api1 (125 mg/kg/day lyophilized Apilarnil), Diabetes + Api2 (250 mg/kg/day lyophilized Apilarnil) and Diabetes + Api3 (500 mg/kg/day lyophilized Apilarnil). Each group consisted of 8 rats. Apilarnil doses were administered by oral gavage with 1 mL of distilled water, 5 days in a week, during the last 6 weeks. The levels of Nrf2, NF-κB, TNF-α, total IRS-1, p-IRS-1, PI3K p85, total Akt, p-Akt, IL-1B, and GLUT4 proteins were determined in target tissues by Western blotting. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol (TC), and triglyceride (TG) levels were detected in the serum. Serum superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), malondialdehyde (MDA), and insulin levels were determined by the ELISA method. According to the data obtained in the study, the application of Apilarnil, compared to the diabetes group, balanced some findings, but did not demonstrate a fully antidiabetic effect.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.